| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:1772.)
© 2002 American Heart Association, Inc.
Brief Rapid Communications |
From the Clinic of Diagnostic Radiology, University of Technology Aachen, Germany.
Correspondence to Arno Buecker, MD, Clinic of Diagnostic Radiology, Pauwelsstr 30, 52057 Aachen, Germany. E-mail buecker{at}rad.rwth-aachen.de
| Abstract |
|---|
|
|
|---|
Methods and Results In vitro investigations were performed with prototypes of balloon-expandable Aachen Resonance Renal MRI Stents dilated to diameters of 3 to 6 mm and placed in an aqueous gadolinium solution (1:25). Phase-contrast and contrast-enhanced T1-weighted gradient echo images were acquired. Renal MRI stents (n=12) were deployed in the renal arteries of 6 pigs. Renal arteries were examined with phase-contrast angiography and with flow measurements before and after stent placement in the stented area, respectively. Additionally, a contrast-enhanced, T1-weighted, spoiled-gradient echo sequence after administration of 0.2 mmol gadolinium-DTPA/kg body weight was performed after stent placement. The visibility of artifacts was analyzed on in vitro and in vivo images by two investigators who knew the stent positions. Stent positions were determined visually (in vitro) or by x-ray angiography (animal experiments). No artifacts were detected independent of the applied imaging sequence and the stent orientation to the main magnetic field.
Conclusion The examined prototypes of fully MR-compatible MRI stents allow artifact-free visualization of the stent lumen with phase-contrast and contrast-enhanced T1-weighted angiography, as well as phase-contrast flow measurements in the stented area.
Key Words: magnetic resonance imaging angiography stents
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
Approval for the animal experiments was obtained from the Official Committee for Animal Affairs of the German government. Experiments were performed on 6 domestic pigs with an average body weight of 55 kg (range, 48 to 61 kg). A premedication of 0.5 mL atropine/10 kg body weight, 2 mL azaperone/10 kg body weight, and 1 mL ketamine/10 kg body weight was applied intramuscularly. Pentobarbital diluted 1:3 with saline solution was injected as needed via a venous access line placed in an ear vein. The animals were intubated and mechanically ventilated.
Before stent placement, a diastolic-triggered 3D phase-contrast angiography was performed (repetition time [TR], 20 ms; echo time [TE], 7 ms; flip angle, 20°; field of view [FOV], 170x120 mm2; matrix, 128x256; slice thickness, 1.5 mm; 50% slice overlap; 40 axial slices; diastolic ECG gating with an acquisition window of 300 ms; and maximum flow velocity, 30 cm/s).5 With the use of the axial images and the calculated maximum intensity projections (MIPs) in the coronal plane, velocity-encoded cine phase-contrast flow measurements (TR, 5.8 ms; TE, 3.6 ms; flip angle, 15°; FOV, 350x175 mm2; matrix 128x256; slice thickness, 5 mm; ECG gating, acquisition of 30 phases of the cardiac cycle; maximum flow velocity, 50 cm/s; 2 signal averages) were performed perpendicular to the course of the renal arteries in the area in which the stent was going to be deployed. Afterward, 12 balloon-mounted Aachen Resonance Renal MRI Stents were placed in the left and right renal arteries of 6 pigs. One stent was placed distally in a first segment branch and dilated to 3 mm. All other stents were placed in the main stem of the renal arteries. One of these stents was dilated with a 6-mm and one with a 7-mm balloon, whereas all other stents were dilated with a 5-mm balloon. Stent positions were documented on x-ray angiography. Orientation of the stents to the main magnetic field B0 were determined on these images assuming a parallel course of the aorta and B0, yielding stent angulations ranging from 36° to 89° (mean 64°).
After stent placement, phase-contrast angiography was repeated. Flow measurements were performed through 10 stents. In two cases, flow measurement was not possible because of a corrupted optical disc. Additionally, a contrast-enhanced T1-weighted gradient echo sequence (TR, 5.4 ms; TE, 1.44 ms; flip angle, 40°; FOV, 450x315 mm2; matrix, 128x512; slice thickness, 1.5 mm; 50% overlap; 50 coronal slices) was acquired with the use of automatic bolus tracking to start the imaging sequence. A double dose of Omniscan (Nycomed) (0.2 mmol/kg body weight) was applied for the MR angiography, and MIPs were calculated.
The calculated MIPs of the phase-contrast and contrast-enhanced angiographies were analyzed by two investigators with regard to the occurrence of artifacts (large or small) or absence of artifacts in the stented area. The regions of stent placement were determined on the digital subtraction angiography images. The Pearson correlation coefficients of the maximum and minimum flow velocities as determined by ECG-triggered phase-contrast MR imaging before and after stent placement were calculated, as well as the slopes of the corresponding regression lines. To investigate possible radiofrequency artifacts, signal intensities in the stents and proximal to them were measured for the gadolinium-enhanced MRA. The values inside and outside the stents were compared by calculating the Pearson correlation coefficient and the slope of the corresponding regression line.
| Results |
|---|
|
|
|---|
|
| Discussion |
|---|
|
|
|---|
In the present study, we examined hand-woven prototypes of Aachen Resonance Renal MRI Stents (Figure 2) made of a special metallic alloy with a high copper content to reduce susceptibility and radiofrequency artifacts. In vitro experiments with standard phase-contrast and contrast-enhanced MRA sequences showed no stent artifacts, even for a stent orientation perpendicular to B0, which in general causes the largest susceptibility artifacts.4 These promising in vitro results were further investigated in an animal model by placing the MRI stents in the renal arteries of pigs. No stent artifacts or signal reduction inside the stents were seen on either the phase-contrast or the contrast-enhanced T1-weighted MRA (Figure 1) independent of the orientation of the stents to B0 or the diameter of the balloon used for stent deployment. This allows the conclusion that the lumen and consequently in-stent restenosis of the MRI stents could become detectable by standard MRA. Stents have been shown to corrupt the results of velocity-encoded phase-contrast imaging,9 although recently, flow measurements were performed successfully in large nitinol stents placed in pulmonary arteries.10 In our case, the lack of stent artifacts made the direct measurement of flow inside the small MRI stents possible, as proved by the good correlation of maximum and minimum flow measured by 2D cine velocity-encoded phase-contrast imaging. The size of susceptibility artifacts is related to the echo time of the MR sequence. The gradient system of our MR scanner (21 mT/m) allowed an echo time of 1.44 ms, and even the substantially longer echo time of the phase-contrast angiography sequence (7 ms) caused no detectable susceptibility artifacts. Therefore, it can be expected that the MRI stents will remain artifact free with other imaging sequences, such as vessel wall imaging. The investigated MRI-compatible stents are virtually invisible on MR images, showing neither susceptibility nor radiofrequency artifacts.
|
Another approach for MR imaging in the presence of stents is to use actively tuned stents as antenna.11 Further experiments will have to show whether the possible advantage of imaging the arterial wall with a stent used as an antenna close to it will prove more feasible and advantageous compared with the simpler approach of creating stents out of an MR-invisible alloy, which does not require additional capacitors to be tuned, as for the active approach. The handmade prototypes lacked a radial force comparable to standard stainless steel stents, a problem that might be overcome by lasering of the stents.
| Conclusions |
|---|
|
|
|---|
| Footnotes |
|---|
Received January 8, 2002; revision received February 21, 2002; accepted February 25, 2002.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. W. Huegli, M. Aschwanden, G. Bongartz, K. Jaeger, H.-G. Heidecker, C. Thalhammer, A.-C. Schulte, C. Hashagen, A. L. Jacob, and D. Bilecen Intraarterial MR Angiography and DSA in Patients with Peripheral Arterial Occlusive Disease: Prospective Comparison Radiology, June 1, 2006; 239(3): 901 - 908. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Martin, D. A. Saloner, T. P. L. Roberts, H. Roberts, O. M. Weber, W. Dillon, S. Cullen, V. Halbach, C. F. Dowd, and R. T. Higashida Carotid Stent Delivery in an XMR Suite: Immediate Assessment of the Physiologic Impact of Extracranial Revascularization AJNR Am. J. Neuroradiol., March 1, 2005; 26(3): 531 - 537. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Spuentrup, A. Ruebben, A. Mahnken, M. Stuber, C. Kolker, T. H. Nguyen, R. W. Gunther, and A. Buecker Artifact-Free Coronary Magnetic Resonance Angiography and Coronary Vessel Wall Imaging in the Presence of a New, Metallic, Coronary Magnetic Resonance Imaging Stent Circulation, March 1, 2005; 111(8): 1019 - 1026. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Hagspiel, D. A. Leung, K. R. Nandalur, J. F. Angle, H. S. Dulai, D. J. Spinosa, A. H. Matsumoto, J. M. Christopher, H. Ahmed, and S. S. Berr Contrast-Enhanced MR Angiography at 1.5 T After Implantation of Platinum Stents: In Vitro and In Vivo Comparison with Conventional Stent Designs Am. J. Roentgenol., January 1, 2005; 184(1): 288 - 294. [Abstract] [Full Text] [PDF] |
||||
![]() |
S K Prasad and D J Pennell Safety of cardiovascular magnetic resonance in patients with cardiovascular implants and devices Heart, November 1, 2004; 90(11): 1241 - 1244. [Full Text] [PDF] |
||||
![]() |
R. M. Botnar, A. Buecker, A. J. Wiethoff, E. C. Parsons Jr, M. Katoh, G. Katsimaglis, R. M. Weisskoff, R. B. Lauffer, P. B. Graham, R. W. Gunther, et al. In Vivo Magnetic Resonance Imaging of Coronary Thrombosis Using a Fibrin-Binding Molecular Magnetic Resonance Contrast Agent Circulation, September 14, 2004; 110(11): 1463 - 1466. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. K. Wacker, R. M. Maes, J. A. Jesberger, S. G. Nour, J. L. Duerk, and J. S. Lewin MR Imaging-Guided Vascular Procedures Using CO2 as a Contrast Agent Am. J. Roentgenol., August 1, 2003; 181(2): 485 - 489. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Spuentrup, A. Ruebben, M. Stuber, R. W. Gunther, and A. Buecker Metallic Renal Artery MR Imaging Stent: Artifact-free Lumen Visualization with Projection and Standard Renal MR Angiography Radiology, June 1, 2003; 227(3): 897 - 902. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Buecker, E. Spuentrup, R. Grabitz, F. Freudenthal, E. G. Muehler, T. Schaeffter, J. J. van Vaals, and R. W. Gunther Magnetic Resonance-Guided Placement of Atrial Septal Closure Device in Animal Model of Patent Foramen Ovale Circulation, July 23, 2002; 106(4): 511 - 515. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |